SCHEMBL7012985

SCHEMBL7012985

COC(=O)CCC(=O)N(C(=O)CCC(=O)OC)c1nc(OC)c(C#N)c(-c2ccccc2F)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SQOR Q9Y6N5 6/20 0.39
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CD274 Q9NZQ7 2/20 0.35
PDCD1 Q15116 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 2/20 0.34
TSHR P16473 1/20 0.34
PDCD1LG2 Q9BQ51 1/20 0.34
ADORA1 P30542 2/20 0.33
ADORA2B P29275 1/20 0.33
ADORA2A P29274 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA4 P48058 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7018846 0.88 ALDH1A1 (0.48) ALDH1A1MAPK1HSD17B10SQORSMN1; SMN2
SCHEMBL7013276 0.87 ALDH1A1 (0.46) ALDH1A1MAPK1HSD17B10SQORKDM4E
SCHEMBL7015455 0.74 ALDH1A1 (0.46) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7017342 0.74 ALDH1A1 (0.52) ALDH1A1MAPK1HSD17B10SQORCD274
SCHEMBL7013301 0.73 ALDH1A1 (0.43) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7018816 0.73 ALDH1A1 (0.48) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7019747 0.73 ALDH1A1 (0.46) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7021979 0.73 ALDH1A1 (0.44) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7018766 0.73 CYP1A2 (0.45) ALDH1A1MAPK1HSD17B10SQORLMNA
SCHEMBL7020733 0.73 ALDH1A1 (0.45) ALDH1A1MAPK1HSD17B10SQORLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232860-A1 Medicine comprising dicyanopyridine derivative ASTELLAS PHARMA INC. (JP) 2003-12-18 US disclosed
EP-1302463-A1 MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232860-A1 Medicine comprising dicyanopyridine derivative KCNN3, KCNN2, KCNN1 ALDH1A1 3292/4885MAPK1 2493/4885HSD17B10 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.